Firefly Neuroscience to Showcase AI-Powered Brain Health Solutions at October Investor Conferences
Curated by THEOUTPOST
On Sat, 12 Oct, 12:01 AM UTC
2 Sources
2 Sources
[1]
Firefly Neuroscience to Participate in Upcoming October Investor Conferences - Firefly Neuroscience (NASDAQ:AIFF)
TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly," "we," or the "Company") AIFF, an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the following October 2024 investor conferences: Maxim Healthcare Virtual Summit Details: Date: October 15-17, 2024 Presentation Format: Fireside Chat with Maxim Analyst, Allen Klee Presentation Day and Time: Thursday, October 17th at 10:00 a.m. ET Webcast: https://investors.fireflyneuro.com/events-presentations ThinkEquity Conference Details: Date: October 30, 2024 Location: Mandarin Oriental Hotel, New York, NY Presentation Day and Time: Wednesday, October 30th at 11:00 a.m. ET Webcast: https://investors.fireflyneuro.com/events-presentations To schedule a one-on-one investor meeting with Mr. Olsen, please contact your representatives at Maxim, ThinkEquity or email KCSA Strategic Communications at Firefly@KCSA.com. About Firefly Firefly AIFF is an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly's FDA-510(k) cleared Brain Network Analytics (BNAâ„¢) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNAâ„¢ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use. Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly's extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNAâ„¢, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician's ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient's outcome. Please visit https://fireflyneuro.com/ for more information. Investor Contact KCSA Strategic Communications Valter Pinto or Jack Perkins (212) 896-1254 Firefly@KCSA.com Media Contact KCSA Strategic Communications Raquel Cona, Vice President (516) 779-2630 Rcona@KCSA.com Market News and Data brought to you by Benzinga APIs
[2]
Firefly Neuroscience to Participate in Upcoming October Investor Conferences By Investing.com
TORONTO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (Firefly, we, or the Company) (NASDAQ: AIFF), an Artificial Intelligence (AI) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that management will participate in the following October 2024 investor conferences: To schedule a one-on-one investor meeting with Mr. Olsen, please contact your representatives at Maxim, ThinkEquity or email KCSA Strategic Communications at Firefly@KCSA.com. About Firefly Firefly (NASDAQ: AIFF) is an Artificial Intelligence (AI) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly's FDA-510(k) cleared Brain Network (LON:NETW) Analytics (BNAâ„¢) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNAâ„¢ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use. Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly's extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNAâ„¢, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician's ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient's outcome. Please visit https://fireflyneuro.com/ for more information.
Share
Share
Copy Link
Firefly Neuroscience, an AI company focused on brain health, announces participation in two major investor conferences in October 2024, highlighting its innovative Brain Network Analytics technology.
Firefly Neuroscience Gears Up for October Investor Conferences
Firefly Neuroscience, Inc. (NASDAQ: AIFF), an innovative AI company focused on improving brain health outcomes, has announced its participation in two significant investor conferences this October. The company, which specializes in developing solutions for patients with neurological and mental disorders, aims to showcase its groundbreaking technology to potential investors and industry professionals [1][2].
Conference Details and Presentation Formats
The company will be participating in two key events:
-
Maxim Healthcare Virtual Summit (October 15-17, 2024):
- Presentation format: Fireside chat with Maxim Analyst, Allen Klee
- Date and time: Thursday, October 17th at 10:00 a.m. ET
- Webcast available on the company's investor relations website [1]
-
ThinkEquity Conference (October 30, 2024):
- Location: Mandarin Oriental Hotel, New York, NY
- Presentation date and time: Wednesday, October 30th at 11:00 a.m. ET
- Webcast also available on the company's investor relations website [1]
Investors interested in one-on-one meetings with Firefly's management can schedule them through representatives at Maxim, ThinkEquity, or by contacting KCSA Strategic Communications [1][2].
Firefly's Innovative AI-Powered Technology
At the heart of Firefly's offerings is its FDA-510(k) cleared Brain Network Analytics (BNAâ„¢) technology. This AI-driven solution is revolutionizing diagnostic and treatment monitoring methods for various neurological and mental health conditions, including depression, dementia, anxiety disorders, concussions, and ADHD [1][2].
The BNAâ„¢ technology was developed using artificial intelligence and machine learning, leveraging Firefly's extensive proprietary database. This database comprises standardized, high-definition longitudinal electroencephalograms (EEGs) from over 17,000 patients, representing twelve disorders as well as clinically normal patients [1][2].
Commercial Launch and Target Markets
Firefly is currently in the process of launching BNAâ„¢ commercially. The company is targeting two primary markets:
- Pharmaceutical companies engaged in drug research and clinical trials
- Medical practitioners for clinical use [1][2]
When used in conjunction with an FDA-cleared EEG system, BNAâ„¢ provides clinicians with comprehensive insights into brain function. These insights can significantly enhance a clinician's ability to accurately diagnose mental and cognitive disorders and evaluate the most suitable therapy or drug to optimize patient outcomes [1][2].
Company Background and Future Prospects
Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, secured patent protection, and achieved FDA clearance for its technology. This positions the company as a potential leader in the growing field of AI-powered neuroscience solutions [1][2].
As Firefly prepares to present at these investor conferences, the company stands at the intersection of artificial intelligence, neuroscience, and healthcare, offering innovative solutions to address the growing global concern surrounding brain health and mental disorders.
Firefly Neuroscience to Showcase AI-Powered Brain Health Solutions at Florida Capital Event
Firefly Neuroscience, an AI company developing innovative brain health solutions, announces its participation in the 8th Annual Florida Capital Event. The company's FDA-cleared Brain Network Analytics technology aims to revolutionize diagnostics and treatment monitoring for neurological and mental disorders.
2 Sources
Firefly Neuroscience Grants Inducement Shares to Executive Chairman, Highlighting AI-Driven Brain Health Solutions
Firefly Neuroscience, an AI company focused on brain health, announces an inducement grant to its Executive Chairman and discusses its innovative Brain Network Analytics technology.
2 Sources
Firefly Neuroscience Appoints Pharmaceutical Industry Veteran Dr. Stella Vnook to Board of Directors
Firefly Neuroscience, a leader in brain health technology, has appointed Dr. Stella Vnook, a pharmaceutical industry veteran, to its Board of Directors. This strategic move aims to leverage Dr. Vnook's extensive experience to advance the company's growth and innovation in brain health solutions.
2 Sources
Firefly Neuroscience Appoints Greg Lipschitz as Executive Chairman, Strengthening AI-Driven Brain Health Solutions
Firefly Neuroscience, an AI company focused on brain health, has appointed Greg Lipschitz as Executive Chairman. This move aims to enhance the company's leadership as it commercializes its AI-driven Brain Network Analytics technology.
2 Sources
iLearningEngines Management to Participate in Upcoming AI Industry Events
iLearningEngines, a leader in AI-powered learning automation and information intelligence, announces participation in key AI industry events. The company's management will share insights on AI applications in various sectors.
2 Sources
Your one-stop AI hub
The Outpost is a comprehensive collection of curated artificial intelligence software tools that cater to the needs of small business owners, bloggers, artists, musicians, entrepreneurs, marketers, writers, and researchers.
The Outpost
Keep in touch
© 2025 TheOutpost.AI All rights reserved